Savant Capital LLC Acquires Shares of 12,971 Puma Biotechnology, Inc. $PBYI

Savant Capital LLC bought a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) during the 2nd quarter, HoldingsChannel reports. The fund bought 12,971 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. CWM LLC boosted its stake in Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 6,450 shares during the last quarter. Causeway Capital Management LLC purchased a new position in shares of Puma Biotechnology during the 1st quarter worth $42,000. Ethic Inc. acquired a new position in shares of Puma Biotechnology during the 2nd quarter valued at about $51,000. Hsbc Holdings PLC purchased a new stake in shares of Puma Biotechnology in the first quarter valued at about $61,000. Finally, Russell Investments Group Ltd. increased its position in Puma Biotechnology by 104,365.0% during the first quarter. Russell Investments Group Ltd. now owns 20,893 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 20,873 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Activity at Puma Biotechnology

In other news, Director Michael Patrick Miller sold 20,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $4.86, for a total transaction of $97,200.00. Following the completion of the transaction, the director directly owned 54,000 shares in the company, valued at $262,440. This trade represents a 27.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 23.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on PBYI shares. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings cut Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Puma Biotechnology Price Performance

Shares of PBYI opened at $4.89 on Friday. The firm has a 50-day simple moving average of $5.04 and a two-hundred day simple moving average of $4.23. The stock has a market cap of $246.41 million, a PE ratio of 4.99 and a beta of 1.35. Puma Biotechnology, Inc. has a 1-year low of $2.58 and a 1-year high of $6.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.09 by $0.12. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. The firm had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.